Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity
Although human liver tumor cells have reduced metabolic functions as compared to primary human hepatocytes (PHH) they are widely used for pre-screening tests of drug metabolism and toxicity. The aim of the present study was to modify liver cancer cell lines in order to improve their drug-metabolizin...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/20/2/347 |
id |
doaj-88bc65d48ec24517b52114e1aaf394ab |
---|---|
record_format |
Article |
spelling |
doaj-88bc65d48ec24517b52114e1aaf394ab2020-11-25T01:48:38ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-01-0120234710.3390/ijms20020347ijms20020347Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic CapacityMarc Ruoß0Georg Damm1Massoud Vosough2Lisa Ehret3Carl Grom-Baumgarten4Martin Petkov5Silvio Naddalin6Ruth Ladurner7Daniel Seehofer8Andreas Nussler9Sahar Sajadian10Siegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanyDepartment of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, 04103 Leipzig, GermanyRoyan Institute for Stem Cell Biology and Technology, Department of Stem Cells and Developmental Biology, Tehran 16635-148, IranSiegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanySiegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanySiegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanyDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, 72076 Tübingen, GermanyDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, 72076 Tübingen, GermanyDepartment of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, 04103 Leipzig, GermanySiegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanySiegfried Weller Institute, BG Trauma Clinic, Eberhard Karls University Tübingen, 72076 Tübingen, GermanyAlthough human liver tumor cells have reduced metabolic functions as compared to primary human hepatocytes (PHH) they are widely used for pre-screening tests of drug metabolism and toxicity. The aim of the present study was to modify liver cancer cell lines in order to improve their drug-metabolizing activities towards PHH. It is well-known that epigenetics is strongly modified in tumor cells and that epigenetic regulators influence the expression and function of Cytochrome P450 (CYP) enzymes through altering crucial transcription factors responsible for drug-metabolizing enzymes. Therefore, we screened the epigenetic status of four different liver cancer cell lines (Huh7, HLE, HepG2 and AKN-1) which were reported to have metabolizing drug activities. Our results showed that HepG2 cells demonstrated the highest similarity compared to PHH. Thus, we modified the epigenetic status of HepG2 cells towards ‘normal’ liver cells by 5-Azacytidine (5-AZA) and Vitamin C exposure. Then, mRNA expression of Epithelial-mesenchymal transition (EMT) marker SNAIL and CYP enzymes were measured by PCR and determinate specific drug metabolites, associated with CYP enzymes by LC/MS. Our results demonstrated an epigenetic shift in HepG2 cells towards PHH after exposure to 5-AZA and Vitamin C which resulted in a higher expression and activity of specific drug metabolizing CYP enzymes. Finally, we observed that 5-AZA and Vitamin C led to an increased expression of Hepatocyte nuclear factor 4α (HNF4α) and E-Cadherin and a significant down regulation of Snail1 (SNAIL), the key transcriptional repressor of E-Cadherin. Our study shows, that certain phase I genes and their enzyme activities are increased by epigenetic modification in HepG2 cells with a concomitant reduction of EMT marker gene SNAIL. The enhancing of liver specific functions in hepatoma cells using epigenetic modifiers opens new opportunities for the usage of cell lines as a potential liver in vitro model for drug testing and development.http://www.mdpi.com/1422-0067/20/2/347tumor cellsepigenetic reprogrammingdrug metabolismhepatoma cell linesprimary human hepatocytes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marc Ruoß Georg Damm Massoud Vosough Lisa Ehret Carl Grom-Baumgarten Martin Petkov Silvio Naddalin Ruth Ladurner Daniel Seehofer Andreas Nussler Sahar Sajadian |
spellingShingle |
Marc Ruoß Georg Damm Massoud Vosough Lisa Ehret Carl Grom-Baumgarten Martin Petkov Silvio Naddalin Ruth Ladurner Daniel Seehofer Andreas Nussler Sahar Sajadian Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity International Journal of Molecular Sciences tumor cells epigenetic reprogramming drug metabolism hepatoma cell lines primary human hepatocytes |
author_facet |
Marc Ruoß Georg Damm Massoud Vosough Lisa Ehret Carl Grom-Baumgarten Martin Petkov Silvio Naddalin Ruth Ladurner Daniel Seehofer Andreas Nussler Sahar Sajadian |
author_sort |
Marc Ruoß |
title |
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity |
title_short |
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity |
title_full |
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity |
title_fullStr |
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity |
title_full_unstemmed |
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity |
title_sort |
epigenetic modifications of the liver tumor cell line hepg2 increase their drug metabolic capacity |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-01-01 |
description |
Although human liver tumor cells have reduced metabolic functions as compared to primary human hepatocytes (PHH) they are widely used for pre-screening tests of drug metabolism and toxicity. The aim of the present study was to modify liver cancer cell lines in order to improve their drug-metabolizing activities towards PHH. It is well-known that epigenetics is strongly modified in tumor cells and that epigenetic regulators influence the expression and function of Cytochrome P450 (CYP) enzymes through altering crucial transcription factors responsible for drug-metabolizing enzymes. Therefore, we screened the epigenetic status of four different liver cancer cell lines (Huh7, HLE, HepG2 and AKN-1) which were reported to have metabolizing drug activities. Our results showed that HepG2 cells demonstrated the highest similarity compared to PHH. Thus, we modified the epigenetic status of HepG2 cells towards ‘normal’ liver cells by 5-Azacytidine (5-AZA) and Vitamin C exposure. Then, mRNA expression of Epithelial-mesenchymal transition (EMT) marker SNAIL and CYP enzymes were measured by PCR and determinate specific drug metabolites, associated with CYP enzymes by LC/MS. Our results demonstrated an epigenetic shift in HepG2 cells towards PHH after exposure to 5-AZA and Vitamin C which resulted in a higher expression and activity of specific drug metabolizing CYP enzymes. Finally, we observed that 5-AZA and Vitamin C led to an increased expression of Hepatocyte nuclear factor 4α (HNF4α) and E-Cadherin and a significant down regulation of Snail1 (SNAIL), the key transcriptional repressor of E-Cadherin. Our study shows, that certain phase I genes and their enzyme activities are increased by epigenetic modification in HepG2 cells with a concomitant reduction of EMT marker gene SNAIL. The enhancing of liver specific functions in hepatoma cells using epigenetic modifiers opens new opportunities for the usage of cell lines as a potential liver in vitro model for drug testing and development. |
topic |
tumor cells epigenetic reprogramming drug metabolism hepatoma cell lines primary human hepatocytes |
url |
http://www.mdpi.com/1422-0067/20/2/347 |
work_keys_str_mv |
AT marcruoß epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT georgdamm epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT massoudvosough epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT lisaehret epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT carlgrombaumgarten epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT martinpetkov epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT silvionaddalin epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT ruthladurner epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT danielseehofer epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT andreasnussler epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity AT saharsajadian epigeneticmodificationsofthelivertumorcelllinehepg2increasetheirdrugmetaboliccapacity |
_version_ |
1725011033885507584 |